Table 3.
Summary of Tuberculosis Preventive Treatment Use in High-Risk Rifampin-Resistant Multidrug-Resistant Tuberculosis Household Contacts by 1 Year
| Characteristic | No TPT, n (%) | Receipt of TPT, n (%) |
|---|---|---|
| Overalla | 528 (96) | 21 (4) |
| High-risk groupb | … | … |
| Age <5 y | 44 (80) | 11 (20) |
| Living with human immunodeficiency virus | 39 (87) | 6 (13) |
| Tuberculosis infection-positive | 445 (99) | 4 (1) |
| Regimen | ||
| INH/LVX/EMB | … | 5 |
| INH | … | 12 |
| INH/MOX/ETH | … | 2 |
| Unknown | … | 2 |
| Country | ||
| Botswana | 18 (100) | 0 (0) |
| Brazil | 9 (90) | 1 (10) |
| Haiti | 29 (100) | 0 (0) |
| India | 129 (98) | 3 (2) |
| Kenya | 5 (83) | 1 (17) |
| Peru | 94 (100) | 0 (0) |
| South Africa | 228 (93) | 16 (7) |
| Thailand | 16 (100) | 0 (0) |
Abbreviations: EMB, ethambutol; ETH, ethionamide; INH, isoniazid; LVX, levofloxacin; MOX, moxifloxacin; TPT, tuberculosis preventive treatment.
Excluding n = 4 individuals for whom receipt of TPT was unknown.
High-risk defined as age <5 years (regardless of human immunodeficiency virus (HIV) and tuberculosis infection (TBI) status); age ≥5 years and diagnosed with HIV (regardless of TBI status); or age ≥5 years, not diagnosed with HIV/unknown and TBI-positive at entry via tuberculin skin test or interferon-gamma release assay.